Justin Kitchens
Family · Stone Mountain, GANPI 1073050449
Payments from drug & device makers
Across 51 payments — averaging $21.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Galderma Laboratories, L.p.$141
- Teva Pharmaceuticals USA, Inc.$124
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$122
- AbbVie$115
- Vanda Pharmaceuticals Inc.$94
- Otsuka America Pharmaceutical, Inc.$77
- plus $424 from 15 others
What the payments were for
- Food & beverage$1,098100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Galderma Laboratories, L.p. | 2 | $141 |
| Teva Pharmaceuticals USA, Inc. | 6 | $124 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 7 | $122 |
| AbbVie(2 entities) | 5 | $115 |
| Vanda Pharmaceuticals Inc. | 5 | $94 |
| Otsuka America Pharmaceutical, Inc. | 4 | $77 |
| Alkermes, Inc. | 2 | $50 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $49 |
| OWP Pharmaceuticals, Inc. | 2 | $44 |
| Axsome Therapeutics, Inc. | 2 | $37 |
| Lundbeck LLC | 2 | $35 |
| Almatica Pharma LLC | 2 | $32 |
| Boston Scientific | 1 | $32 |
| E.r. Squibb & Sons, L.L.C. | 1 | $28 |
| Neos Therapeutics, LP | 1 | $22 |
| Indivior Inc. | 1 | $20 |
| Neurocrine Biosciences, Inc. | 1 | $17 |
| Braeburn Inc. | 1 | $16 |
| Johnson & Johnson | 1 | $15 |
| Collegium Pharmaceutical, Inc. | 1 | $14 |
| Ironshore Pharmaceuticals Inc. | 1 | $13 |
How this compares
$1,098 in reported general payments places this provider in the 65th percentile of 6,258 family providers in Georgia.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VraylarCariprazine Hcl | 37 | $52,022 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 59 | $9,682 |
| SuboxoneBuprenorphine Hcl/Naloxone Hcl | 11 | $9,090 |
| Aripiprazole | 147 | $7,149 |
| Quetiapine Fumarate | 219 | $2,804 |
| ZubsolvBuprenorphine Hcl/Naloxone Hcl | 12 | $2,594 |
| Ziprasidone Hcl | 63 | $2,275 |
| Duloxetine Hcl | 153 | $2,245 |
| Lamotrigine | 248 | $1,891 |
| Bupropion XlBupropion Hcl | 133 | $1,668 |
| Clonazepam | 308 | $1,449 |
| Trazodone Hcl | 170 | $964 |
| Escitalopram Oxalate | 146 | $867 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 90 | $817 |
| Buspirone Hcl | 70 | $731 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieVraylar | $115 | $52,02237 claims |
| Indivior Inc.Suboxone | $20 | $9,09011 claims |
| Almatica Pharma LLCSertraline Hcl | $32 | $33671 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 6,258 family providers in Georgia.
Other family in Stone Mountain
- Theresa Harvey-GilliardStone Mountain$22K
- Allie McAllisterMarietta$299K
- Tonita WashingtonLawrenceville$153K
- Erin HenryLawrenceville$135K
- Trisha RomanPeachtree City$134K
- Lori ReedMarietta$106K
- Julia BranchCumming$102K
- Hannah BanachWaycross$85K
- Morgan GroothandEvans$81K
- Anna Carolina WrightLilburn$69K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.